Merck Is Poised To Outperform In 2023


  • Merck & Co., Inc. substantially outperformed in 2022.
  • Merck achieved a series of positive trial outcomes and approvals.
  • Global revenue growth has been solid.
  • The Wall Street consensus rating is a buy, but MRK’s current share price is close to the 12-month price target.
  • The market-implied outlook (calculated from options prices) is bullish through 2023.

Merck Canada head office in Kirkland, Quebec, Canada.


Merck & Co., Inc. (NYSE:MRK) was the top-performing large U.S. pharma stock for 2022, and the shares had their best year since 1995. MRK had a total return of 48.4% for 2022, as compared to

MRK stock price chart

Seeking Alpha

Outlook for Merck

Seeking Alpha

Merck average price target


Merck Wall St Analysts rating

Seeking Alpha

Merck stock market-implied outlook

Geoff Considine

market-implied outlook for Merck

Geoff Considine

Merck stock returns

Geoff Considine

Disclosure: I/we have a beneficial long position in the shares of MRK either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Leave a Reply

Your email address will not be published. Required fields are marked *